Keywords: Merck KGaA, Idera Pharma, IMO-2055, Cancer indications, Global rights

Merck KGaA returns rights to IMO-2055 in oncology to Idera Pharma

Article | 01 December 2011

USA-based Idera Pharmaceuticals (Nasdaq: IDRA) revealed yesterday that it has regained global rights to IMO-2055, an agonist of Toll-like Receptor ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Merck KGaA

Idera Pharmaceuticals

Go to company listing